17
induced pain flare after palliative radiotherapy for bone
metastases-a pilot study. Support Care Cancer 15(6): 643-647,
6/2007.
8.
Cleeland CS. The measurement of pain from metastatic bone
disease: capturing the patient's experience. Clin Cancer Res
12(20 Pt 2): 6236s-6242s, 10/2006.
9.
Colella J, Scrofine S, Galli B, Knorr-Mulder C, Gejerman G,
Scheuch J, Lanteri V, Siegel A, Levey S, Watson R, Block M,
Sawczuk I. Prostate HDR radiation therapy: a comparative
study evaluating the effectiveness of pain management with
peripheral PCA vs. PCEA. Urol Nurs 26(1): 57-61, 2/2006.
10. Depuy V, Anstrom KJ, Castel LD, Schulman KA, Weinfurt KP,
Saad F. Effects of skeletal morbidities on longitudinal patient-
reported outcomes and survival in patients with metastatic
prostate cancer. Support Care Cancer 15(7): 869-876, 7/2007.
11. Goetz MP, Callstrom MR, Charboneau JW, Farrell MA, Maus
TP, Welch TJ, Wong GY, Sloan JA, Novotny PJ, Petersen IA,
Beres RA, Regge D, Capanna R, Saker MB, Gronemeyer DH,
Gevargez A, Ahrar K, Choti MA, de Baere TJ, Rubin J.
Percutaneous image-guided radiofrequency ablation of
painful metastases involving bone: a multicenter study. J Clin
Oncol 22(2): 300-306, 1/2004.
12. Hadi S, Fan G, Hird AE, Kirou-Mauro A, Filipczak LA, Chow E.
Symptom clusters in patients with cancer with metastatic
bone pain. J Palliat Med 11(4): 591-600, 5/2008.
13. Halabi S, Vogelzang NJ, Kornblith AB, Ou SS, Kantoff PW,
Dawson NA, Small EJ. Pain predicts overall survival in men with
metastatic castration-refractory prostate cancer. J Clin Oncol
26(15): 2544-2549, 5/2008.
14. Harris K, Pugash R, David E, Yee A, Sinclair E, Myers J, Chow E.
Percutaneous cementoplasty of lytic metastasis in left
acetabulum. Curr Oncol 14(1): 4-8, 2/2007.
15. Harris K, Li K, Flynn C, Chow E. Worst, average or current pain
in the brief pain inventory: Which should be used to calculate
the response to palliative radiotherapy in patients with bone
metastases? Clinical Oncology 19(7): 523-527, 9/2007.
18
16. Hartsell WF, Scott CB, Bruner DW, Scarantino CW, Ivker RA,
Roach M, III, Suh JH, Demas WF, Movsas B, Petersen IA, Konski
AA, Cleeland CS, Janjan NA, DeSilvio M. Randomized trial of
short- versus long-course radiotherapy for palliation of painful
bone metastases. J Natl Cancer Inst 97(11): 798-804, 6/2005.
17. Hong SJ, Cho KS, Choi HY, Ahn H, Kim CS, Chung BH. A
prospective, multicenter, open-label trial of zoledronic acid in
patients with hormone refractory prostate cancer. Yonsei
Medical Journal 48(6): 1001-1008, 12/2007.
18. Janjan NA, Payne R, Gillis T, Podoloff D, Libshitz HI, Lenzi R,
Theriault R, Martin C, Yasko A. Presenting symptoms in patients
referred to a multidisciplinary clinic for bone metastases. J
Pain Symptom Manage 16(3): 171-178, 9/1998.
19. Kornblith AB, Herndon JE, Zuckerman E, Godley PA, Savarese
D, Vogelzang NJ. The impact of docetaxel, estramustine, and
low dose hydrocortisone on the quality of life of men with
hormone refractory prostate cancer and their partners: a
feasibility study. Ann Oncol 12(5): 633-641, 5/2001.
20. Loblaw A, Chow E, Panzarella T, Tsao M, Barnes EA, Sinclair E,
Farhadian M, Danjoux C. Dexamethasone for the prophylaxis
of radiation-induced pain flare following palliative
radiotherapy for bone metastases. Int J Radiat Oncol Biol Phys
66(3 Supplement 1): S525, 11/2006.
21. Lothman H, Heatley S, Lipton A. Zoledronic acid (zol) provides
long-term palliation of bone pain in breast cancer (bc)
patients (pts) with bone metastases. Eur J Oncol Nurs 10(3):
225-226, 7/2006.
22. Mystakidou K, Katsouda E, Parpa E, Kouskouni E, Chondros C,
Tsiatas ML, Galanos A, Vlahos L. A prospective randomized
controlled clinical trial of zoledronic acid for bone metastases.
Am J Hosp Palliat Care 23(1): 41-50, 1/2006.
23. Nishio M, Sano M, Tamaki Y, Fujii H, Shima Y, Fujimoto H, Kubo
A, Koizumi K, Tokuda Y, Adachi S, Sumiyoshi Y, Hasegawa T,
Eguchi K. [A multicenter study to determine the efficacy and
safety of strontium (89Sr) chloride for palliation of painful bony
